| Issuer: | Prometic Life Sciences Inc. (the "Company") |
| Securities: | Common Shares |
| Symbol(s): | PLI |
| Delisting Review Status: | TSX has determined that the Company has regained compliance with the requirements for continued listing. |
| Additional Information: | Please refer to TSX Bulletin #2019-0278 dated April 16, 2019. |
| TSX contact: | Chris Birkett, Director, Toronto Stock Exchange |
TMX Group Limited and its affiliates do not endorse or recommend any securities issued by any companies identified on, or linked through, this site. Please seek professional advice to evaluate specific securities or other content on this site. All content (including any links to third party sites) is provided for informational purposes only (and not for trading purposes), and is not intended to provide legal, accounting, tax, investment, financial or other advice and should not be relied upon for such advice. The views, opinions and advice of any third party reflect those of the individual authors and are not endorsed by TMX Group Limited or its affiliates. TMX Group Limited and its affiliates have not prepared, reviewed or updated the content of third parties on this site or the content of any third party sites, and assume no responsibility for such information.
